This site is intended for Healthcare professionals only.
×

Hetero launches generic Lapatinib under the brand name HERTAB in India


Hetero launches generic Lapatinib under the brand name HERTAB in India

HERTAB (Lapatinib) is an oral therapy indicated for the treatment of postmenopausal women with HER2-positive advanced breast cancer patients whose disease has progressed after taking Trastuzumab therapy.

Hyderabad: Hetero, one of India’s generic pharmaceutical companies and producer of anti-retroviral drugs, recently announced the launch of generic version of Lapatinib (250 mg) tablets in India.

The product is marketed and distributed under the brand name ‘HERTAB’ by Hetero Healthcare Ltd. It is made available in two SKUs, each consisting of 30 tablets and 150 tablets.

HERTAB (Lapatinib) is an oral therapy indicated for the treatment of postmenopausal women with HER2-positive advanced breast cancer patients whose disease has progressed after taking Trastuzumab therapy.

Lapatinib is used in combination with other medication Capecitabine or Letrozole, which together, inhibit the growth of cancer cells in patients.

Hetero’s business areas spread across APIs, generics, biosimilars, custom pharmaceutical services and branded generics. The company is globally recognized for Research and Development, manufacturing and commercialization of a wide range of products.

Also Read: Hetero Labs Limited acquires Tarbis Farma in Spain

The following two tabs change content below.
Farhat Nasim

Farhat Nasim

Farhat Nasim joined Medical Dialogue as Reporter in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier's College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751


Source: self
0 comment(s) on Hetero launches generic Lapatinib under the brand name HERTAB in India

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted